1. Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C. & Sandborn, W. J. Ulcerative colitis. Lancet 380, 1606–1619 (2012).
2. Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G. & Long, M. D. ACG clinical guideline: Ulcerative colitis in adults.
Am. J. Gastroenterol. 114, 384–413 (2019).
3. Raine, T. et al. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J. Crohns Colitis. 16, 2–17 (2022).
4. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
5. Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Gastroenterology. 142, 257–265 (2012).
6. Sandborn, W. J. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe
ulcerative colitis. Gastroenterology. 146, 85–95 (2014).
7. Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).
8. Fedyk, E. R. et al. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in
primates. Inflamm. Bowel Dis. 18, 2107–2119 (2012).
9. Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
10. Amiot, A. et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin.
Gastroenterol. Hepatol. 14, 1593–1601 (2016).
11. Kopylov, U. et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli realworld experience. Inflamm. Bowel Dis. 23, 404–408 (2017).
12. Gisbert, J. P. & Chaparro, M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in
patients with inflammatory bowel disease: From basic science to clinical practice. J. Crohns Colitis 14, 694–709 (2020).
13. Kim, E. M. et al. Mucosal eosinophilia is an independent predictor of vedolizumab efficacy in inflammatory bowel diseases.
Inflamm. Bowel Dis. 26, 1232–1238 (2020).
14. Neurath, M. F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329–342 (2014).
15. Mosli, M. H. et al. Development and validation of a histological index for UC. Gut 66, 50–58 (2017).
16. Soler, D. et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody
in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330, 864–875 (2009).
17. Narula, N. et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am. J. Gastroenterol.
113, 1345. https://doi.org/10.1038/s41395-018-0162-0 (2018).
18. Shelton, E. et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm. Bowel
Dis. 21, 2879–2885 (2015).
19. Olsen, T. et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.
Scand. J. Gastroenterol. 42, 1312–1320 (2007).
20. Andersson, E. et al. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLoS. One
12, e0186142 (2017).
21. Mavroudis, G. et al. Mucosal and systemic immune profiles differ during early and late phases of the disease in patients with active
ulcerative colitis. J. Crohns Colitis. 13, 1450–1458 (2019).
22. Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434 (2007).
23. Spits, H. et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013).
24. Artis, D. & Spits, H. The biology of innate lymphoid cells. Nature 517, 293–301 (2015).
25. Creyns, B. et al. Biological therapy in inflammatory bowel disease patients partly restores intestinal innate lymphoid cell subtype
equilibrium. Front. Immunol. 11, 1847. https://doi.org/10.3389/fimmu.2020.01847 (2020).
26. Oshima, T. et al. Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1:
Implications for inflammatory bowel disease therapy. Aliment Pharmacol. Ther. 15, 1211–1218 (2001).
27. Pitzalis, C. et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: An additional mechanism
for their anti-inflammatory and immunosuppressive effect. J. Immunol. 158, 5007–5016 (1997).
28. Investigative Research Group for Intractable Inflammatory Bowel Disorders (Watanabe group). Diagnostic criteria for ulcerative
colitis (2012 revision). Annual reports of the research group of intractable inflammatory bowel disease subsidized by the Ministry
of Health, Labour and Welfare of Japan. (Japanese, 2013).
29. Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625–1629 (1987).
30. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458
(2013).
Acknowledgements
We thank the members of the Kobe IBD Study Group for their efforts in patient enrollment. The members of the
Kobe IBD Study Group not included as authors are as follows: Junya Ando (Ando Gastroenterology IBD Clinic),
Michitaka Kohashi (Kakogawa Central City Hospital), Mari Noda (Osaka Saiseikai Nakatsu Hospital), Hidenori
Tanaka (Sanda City Hospital). We would like to thank Editage for English language editing.
Author contributions
All authors contributed to the study conception and design. The material preparation, data collection and analysis
were performed by H.M. and N.H. The first draft of the manuscript was written by H.M., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Scientific Reports |
Vol:.(1234567890)
(2023) 13:20262 |
https://doi.org/10.1038/s41598-023-47618-3
www.nature.com/scientificreports/
Competing interests The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to N.H.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
© The Author(s) 2023
Scientific Reports |
(2023) 13:20262 |
https://doi.org/10.1038/s41598-023-47618-3
Vol.:(0123456789)
...
論文の公開元へ
